Healthcare Industry News: Janssen
News Release - April 3, 2007
Angiotech appoints Chris Dennis as Senior Vice President, Sales and MarketingVANCOUVER, April 3 (HSMN NewsFeed) - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced the appointment of Chris Dennis as Senior Vice President, Sales and Marketing.
Mr. Dennis brings to Angiotech a broad background in marketing, sales and general management in the health care sector including over 17 years of experience working for various subsidiaries of Johnson & Johnson (J&J).
Prior to joining Angiotech, Mr. Dennis was Global President of J&J's OrthoNeutrogena company (pharmaceuticals and aesthetic devices), where he was responsible for overall strategy and business growth initiatives. Previously, he held the position of Vice President, Marketing & Sales for Janssen Ortho, Inc. (pharmaceuticals), where he managed the sales and marketing of a wide range of prescription medications. Mr. Dennis also held the position of President, LifeScan Canada Ltd. (medical devices), where he oversaw the sales, marketing and distribution of diagnostic products for people with diabetes. He also held a number of sales and management roles at McNeil Consumer Products, a J&J company, and Bristol Myers Products Canada.
"This time last year, Angiotech was a company with significant expertise in R&D and a substantial intellectual property portfolio. Today, we have built on that foundation and grown to become a fully integrated and commercialized specialty pharmaceutical and medical device company. With our comprehensive manufacturing, sales and marketing capabilities, we're pleased that Angiotech is attracting industry leaders like Chris to our senior management team," said Dr. William Hunter, President and CEO of Angiotech.
As Senior Vice President, Sales and Marketing, Mr. Dennis will be focused on building a global sales and marketing organization with a commercialization strategy that includes Angiotech's five identified focus markets. Angiotech anticipates a number of important product launches in 2007, including the Quill® SRS wound closure system and Angiotech's anti-infective 5-FU CVC.
"Recognizing Chris' extensive experience in both the pharmaceutical and medical device industries, we're confident he will help us build a strong global sales and marketing division, and we're excited that he shares our vision of a fully-commercialized Angiotech," added Dr. Hunter.
Note on Forward Looking Statements
Statements contained in this press release that are not based on historical fact, including without limitation statements containing the words "believes," "may," "plans," "will," "estimate," "continue," "anticipates," "intends," "expects" and similar expressions, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and constitute "forward-looking information" within the meaning of applicable Canadian securities laws. All such statements are made pursuant to the "safe harbor" provisions of applicable securities legislation. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following; general economic and business conditions, both nationally and in the regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this report to differ materially from our actual results. These operating risks include; poor performance of the product in the clinical setting; adverse events related to the use of the product; improper estimation of the size of the product markets; adverse results or unexpected delays in clinical development processes; our ability to attract and retain qualified personnel; our ability to successfully complete preclinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the continued availability of capital to finance our activities; our ability to continue to integrate into our business the operations of American Medical Instruments Holdings, Inc. and our ability to achieve the operational and other synergies and the other commercial or financial benefits expected as a result of that acquisition; and any other factors referenced in our annual information form and other filings with the applicable Canadian securities regulatory authorities or the SEC.
Given these uncertainties, assumptions and risk factors, readers are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained in this prospectus to reflect future results, events or developments.
Quill® is a registered trademark of Quill Medical, Inc., a wholly-owned subsidiary of Angiotech Pharmaceuticals, Inc.© 2007 Angiotech Pharmaceuticals, Inc. All rights reserved.
Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with 17 facilities in 6 countries and over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP), please visit our website at www.angiotech.com.
Source: Angiotech Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.